Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Down Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 53Vincristine 33blinatumomab 30Prednisone 28Methotrexate 28Cytarabine 26Dexamethasone 24Specimen Handling 21Rituximab 21Doxorubicin 20merphos 19Mercaptopurine 19Etoposide 18prednylidene 17fludarabine 17deltacortene 17Calcium Dobesilate 17Biopsy 17dexamethasone acetate 16dexamethasone 21-phosphate 16auricularum 16N,N-dicyclohexyl-isoborneol-10-sulfonamide 16azathiopurine 15Inotuzumab Ozogamicin 15pegaspargase 14venetoclax 13Leucovorin 13CT-P10 13Asparaginase 13Spinal Puncture 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Leyk × 1 year × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡